Intracervical vasopressin to help hysteroscopic removal of retained pregnancy tissue.
Intracervical Vasopressin for Completion of Hysteroscopic Removal of Retained Products of Conception
This test checks whether injecting vasopressin into the cervix during hysteroscopic removal helps women 18–51 have complete removal of retained pregnancy tissue.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years to 51 Years |
| Sex | Female |
| Sponsor | Prisma Health-Upstate Academic / other |
| Locations | 1 site (Greenville, South Carolina) |
| Trial ID | NCT07102615 on ClinicalTrials.gov |
What this trial studies
This double-blind randomized controlled trial compares intracervical vasopressin to saline placebo given during hysteroscopic removal of retained products of conception in women aged 18–51. Participants are randomized to receive either vasopressin or a placebo injection into the cervix at the time of the procedure. The primary outcome is surgical completion, defined as completing hysteroscopic removal without converting to suction because of bleeding or poor visualization. Secondary outcomes include intraoperative bleeding, operative time, and fluid deficit measurements.
Who should consider this trial
Good fit: Women aged 18–51 undergoing hysteroscopic surgical management for retained products of conception after miscarriage, abortion, or delivery who are hemodynamically stable and able to consent.
Not a fit: Patients with active heavy bleeding, hemodynamic instability, known allergy to vasopressin, suspected intrauterine arteriovenous malformation, or inability to consent are unlikely to benefit or are excluded.
Why it matters
Potential benefit: If successful, this could increase complete hysteroscopic removals of RPOC with less bleeding and fewer conversions to suction.
How similar studies have performed: Vasopressin has been used in other gynecologic surgeries to reduce bleeding, but its intracervical use specifically for improving hysteroscopic removal of RPOC is not well-established.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Women * Aged 18-51 * Undergoing surgical management for retained products of conception, postpartum retained products of conception or 1st trimester missed or incomplete abortion Exclusion Criteria: * Hemodynamic instability * Active hemorrhage- soaking pad/hour * Allergy to vasopressin * Concern for intrauterine arteriovenous malformation * Inability to consent
Where this trial is running
Greenville, South Carolina
- The OB/GYN Center — Greenville, South Carolina, United States (Recruiting)
Study contacts
- Study coordinator: Patti Parker, BSN
- Email: patti.parker@prismahealth.org
- Phone: 864-455-1510
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.